Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins

Keith Cartwright; Rhonwen Morris; Hans Rümke; Andrew Fox; Borrow Ray Borrow; Norman Begg; Peter Richmond; Jan Poolman

doi:10.1016/S0264-410X(99)00044-4

Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins

Keith Cartwright^*, Rhonwen Morris, Hans Rümke, Andrew Fox, Borrow Ray Borrow, Norman Begg, Peter Richmond, Jan Poolman

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

158 Citations (Scopus)

Abstract

The development of effective vaccines against serogroup B meningococci is of great public health importance. We assessed a novel genetically engineered vaccine containing six meningococcal class 1 (PorA) outer membrane proteins representing 80% of prevalent strains in the UK. 103 infants were given the meningococcal vaccine at ages 2, 3 and 4 months with routine infant immunisations, with a fourth dose at 12-18 months. The vaccine was well tolerated. Three doses evoked good immune responses to two of six meningococcal strains expressing PorA proteins contained in the vaccine. Following a fourth dose, larger bactericidal responses to all six strains were observed, suggesting that the initial course had primed memory lymphocytes and revaccination stimulated a booster response. This hexavalent PorA meningococcal vaccine was safe and evoked encouraging immune responses in infants. Vaccines of this type warrant further development and evaluation.

Original language	English
Pages (from-to)	2612-2619
Number of pages	8
Journal	Vaccine
Volume	17
Issue number	20-21
DOIs	https://doi.org/10.1016/S0264-410X(99)00044-4
Publication status	Published - 4 Jun 1999

Bibliographical note

Funding Information:
The study was funded primarily by the UK Department of Health but also by the RIVM and by the National Meningitis Trust. The RIVM, Bilthoven, The Netherlands, provided the meningococcal vaccines and isogenic test strains.

Keywords

Infants
Meningococcal vaccine
PorA

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0264-410X(99)00044-4

Cite this

@article{78a8bce476d4495db2ec6ba1d6d9fe47,

title = "Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins",

abstract = "The development of effective vaccines against serogroup B meningococci is of great public health importance. We assessed a novel genetically engineered vaccine containing six meningococcal class 1 (PorA) outer membrane proteins representing 80% of prevalent strains in the UK. 103 infants were given the meningococcal vaccine at ages 2, 3 and 4 months with routine infant immunisations, with a fourth dose at 12-18 months. The vaccine was well tolerated. Three doses evoked good immune responses to two of six meningococcal strains expressing PorA proteins contained in the vaccine. Following a fourth dose, larger bactericidal responses to all six strains were observed, suggesting that the initial course had primed memory lymphocytes and revaccination stimulated a booster response. This hexavalent PorA meningococcal vaccine was safe and evoked encouraging immune responses in infants. Vaccines of this type warrant further development and evaluation.",

keywords = "Infants, Meningococcal vaccine, PorA",

author = "Keith Cartwright and Rhonwen Morris and Hans R{\"u}mke and Andrew Fox and {Ray Borrow}, Borrow and Norman Begg and Peter Richmond and Jan Poolman",

note = "Funding Information: The study was funded primarily by the UK Department of Health but also by the RIVM and by the National Meningitis Trust. The RIVM, Bilthoven, The Netherlands, provided the meningococcal vaccines and isogenic test strains.",

year = "1999",

month = jun,

day = "4",

doi = "10.1016/S0264-410X(99)00044-4",

language = "English",

volume = "17",

pages = "2612--2619",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "20-21",

}

TY - JOUR

T1 - Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins

AU - Cartwright, Keith

AU - Morris, Rhonwen

AU - Rümke, Hans

AU - Fox, Andrew

AU - Ray Borrow, Borrow

AU - Begg, Norman

AU - Richmond, Peter

AU - Poolman, Jan

N1 - Funding Information: The study was funded primarily by the UK Department of Health but also by the RIVM and by the National Meningitis Trust. The RIVM, Bilthoven, The Netherlands, provided the meningococcal vaccines and isogenic test strains.

PY - 1999/6/4

Y1 - 1999/6/4

N2 - The development of effective vaccines against serogroup B meningococci is of great public health importance. We assessed a novel genetically engineered vaccine containing six meningococcal class 1 (PorA) outer membrane proteins representing 80% of prevalent strains in the UK. 103 infants were given the meningococcal vaccine at ages 2, 3 and 4 months with routine infant immunisations, with a fourth dose at 12-18 months. The vaccine was well tolerated. Three doses evoked good immune responses to two of six meningococcal strains expressing PorA proteins contained in the vaccine. Following a fourth dose, larger bactericidal responses to all six strains were observed, suggesting that the initial course had primed memory lymphocytes and revaccination stimulated a booster response. This hexavalent PorA meningococcal vaccine was safe and evoked encouraging immune responses in infants. Vaccines of this type warrant further development and evaluation.

AB - The development of effective vaccines against serogroup B meningococci is of great public health importance. We assessed a novel genetically engineered vaccine containing six meningococcal class 1 (PorA) outer membrane proteins representing 80% of prevalent strains in the UK. 103 infants were given the meningococcal vaccine at ages 2, 3 and 4 months with routine infant immunisations, with a fourth dose at 12-18 months. The vaccine was well tolerated. Three doses evoked good immune responses to two of six meningococcal strains expressing PorA proteins contained in the vaccine. Following a fourth dose, larger bactericidal responses to all six strains were observed, suggesting that the initial course had primed memory lymphocytes and revaccination stimulated a booster response. This hexavalent PorA meningococcal vaccine was safe and evoked encouraging immune responses in infants. Vaccines of this type warrant further development and evaluation.

KW - Infants

KW - Meningococcal vaccine

KW - PorA

UR - http://www.scopus.com/inward/record.url?scp=0033523057&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(99)00044-4

DO - 10.1016/S0264-410X(99)00044-4

M3 - Article

C2 - 10418910

AN - SCOPUS:0033523057

SN - 0264-410X

VL - 17

SP - 2612

EP - 2619

JO - Vaccine

JF - Vaccine

IS - 20-21

ER -

Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this